...
adag-img

Adagene Inc, Common Stock

ADAG

NMQ

$2.1

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$108.46M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.49K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.58
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.6 L
$4.38 H
$2.1

About Adagene Inc, Common Stock

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameADAGSectorS&P500
1-Week Return-17%-3.39%0.2%
1-Month Return-6.25%-1.92%2.72%
3-Month Return-9.87%-10.54%7.31%
6-Month Return-16.33%-4.47%10.44%
1-Year Return43.34%4.06%27.53%
3-Year Return-72.04%0.94%30.88%
5-Year Return-93%36.67%89.21%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue480.00K480.00K10.18M9.29M18.11M[{"date":"2019-12-31","value":2.65,"profit":true},{"date":"2020-12-31","value":2.65,"profit":true},{"date":"2021-12-31","value":56.18,"profit":true},{"date":"2022-12-31","value":51.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit480.00K480.00K10.18M9.29M18.11M[{"date":"2019-12-31","value":2.65,"profit":true},{"date":"2020-12-31","value":2.65,"profit":true},{"date":"2021-12-31","value":56.18,"profit":true},{"date":"2022-12-31","value":51.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%100.00%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses19.65M19.65M82.54M93.21M41.83M[{"date":"2019-12-31","value":21.08,"profit":true},{"date":"2020-12-31","value":21.08,"profit":true},{"date":"2021-12-31","value":88.55,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":44.88,"profit":true}]
Operating Income(19.17M)(19.17M)(72.36M)(83.92M)(23.72M)[{"date":"2019-12-31","value":-1916965000,"profit":false},{"date":"2020-12-31","value":-1916965000,"profit":false},{"date":"2021-12-31","value":-7236408900,"profit":false},{"date":"2022-12-31","value":-8392068300,"profit":false},{"date":"2023-12-31","value":-2371986600,"profit":false}]
Total Non-Operating Income/Expense3.52M1.54M600.17K4.09M9.64M[{"date":"2019-12-31","value":36.53,"profit":true},{"date":"2020-12-31","value":15.96,"profit":true},{"date":"2021-12-31","value":6.23,"profit":true},{"date":"2022-12-31","value":42.45,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(16.43M)(16.43M)(71.48M)(79.51M)(17.25M)[{"date":"2019-12-31","value":-1643230800,"profit":false},{"date":"2020-12-31","value":-1643230800,"profit":false},{"date":"2021-12-31","value":-7147632200,"profit":false},{"date":"2022-12-31","value":-7951279200,"profit":false},{"date":"2023-12-31","value":-1725496200,"profit":false}]
Income Taxes861.57K3.16K1.70M459.06K1.69M[{"date":"2019-12-31","value":50.63,"profit":true},{"date":"2020-12-31","value":0.19,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":26.98,"profit":true},{"date":"2023-12-31","value":99.4,"profit":true}]
Income After Taxes(17.29M)(16.44M)(73.18M)(79.97M)(18.95M)[{"date":"2019-12-31","value":-1729388000,"profit":false},{"date":"2020-12-31","value":-1643547200,"profit":false},{"date":"2021-12-31","value":-7317793500,"profit":false},{"date":"2022-12-31","value":-7997184700,"profit":false},{"date":"2023-12-31","value":-1894637000,"profit":false}]
Income From Continuous Operations(16.43M)(16.43M)(73.18M)(79.97M)(18.95M)[{"date":"2019-12-31","value":-1643230800,"profit":false},{"date":"2020-12-31","value":-1643230800,"profit":false},{"date":"2021-12-31","value":-7317793500,"profit":false},{"date":"2022-12-31","value":-7997184700,"profit":false},{"date":"2023-12-31","value":-1894637000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(17.29M)(16.44M)(73.18M)(79.97M)(18.95M)[{"date":"2019-12-31","value":-1729388000,"profit":false},{"date":"2020-12-31","value":-1643547200,"profit":false},{"date":"2021-12-31","value":-7317793500,"profit":false},{"date":"2022-12-31","value":-7997184700,"profit":false},{"date":"2023-12-31","value":-1894637000,"profit":false}]
EPS (Diluted)(1.79)(3.20)(1.95)(3.21)-[{"date":"2019-12-31","value":-179.48,"profit":false},{"date":"2020-12-31","value":-320.41,"profit":false},{"date":"2021-12-31","value":-195,"profit":false},{"date":"2022-12-31","value":-321,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ADAG
Cash Ratio 2.42
Current Ratio 2.50
Quick Ratio 2.50

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ADAG
ROA (LTM) -19.59%
ROE (LTM) -45.70%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ADAG
Debt Ratio Lower is generally better. Negative is bad. 0.44
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.56

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ADAG
Trailing PE NM
Forward PE NM
P/S (TTM) 113.97
P/B 1.64
Price/FCF NM
EV/R 22.17
EV/Ebitda 1.12

FAQs

What is Adagene Inc share price today?

Adagene Inc (ADAG) share price today is $2.1

Can Indians buy Adagene Inc shares?

Yes, Indians can buy shares of Adagene Inc (ADAG) on Vested. To buy Adagene Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ADAG stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Adagene Inc be purchased?

Yes, you can purchase fractional shares of Adagene Inc (ADAG) via the Vested app. You can start investing in Adagene Inc (ADAG) with a minimum investment of $1.

How to invest in Adagene Inc shares from India?

You can invest in shares of Adagene Inc (ADAG) via Vested in three simple steps:

  • Click on Sign Up or Invest in ADAG stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Adagene Inc shares
What is Adagene Inc 52-week high and low stock price?

The 52-week high price of Adagene Inc (ADAG) is $4.38. The 52-week low price of Adagene Inc (ADAG) is $1.6.

What is Adagene Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Adagene Inc (ADAG) is

What is Adagene Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Adagene Inc (ADAG) is 1.64

What is Adagene Inc dividend yield?

The dividend yield of Adagene Inc (ADAG) is 0.00%

What is the Market Cap of Adagene Inc?

The market capitalization of Adagene Inc (ADAG) is $108.46M

What is Adagene Inc’s stock symbol?

The stock symbol (or ticker) of Adagene Inc is ADAG

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top